In preclinical studies, NRG-1 was also protective against doxorubicin-induced or trastuzumab-induced cardiotoxicity, a common unwanted side-effect related to drugs used in breast cancer patients [152, 153]. The gene discussed is NRG1; the disease is breast carcinoma.